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Original StudieS
Background: There are concerns about the effects of in utero exposure to 
antiretroviral drugs (ARVs) on the development of HIV-exposed but unin-
fected (HEU) children. The aim of this study was to evaluate whether in 
utero exposure to ARVs is associated with lower birth weight/height and 
reduced growth during the first 2 years of life.
Methods: This cohort study was conducted among HEU infants born 
between 1996 and 2010 in Tertiary children’s hospital in Rio de Janeiro, 
Brazil. Weight was measured by mechanical scale, and height was measured 
by measuring board. Z-scores for weight-for-age (WAZ), length-for-age 
(LAZ) and weight-for-length were calculated. We modeled trajectories by 
mixed-effects models and adjusted for mother’s age, CD4 cell count, viral 
load, year of birth and family income.
Results: A total of 588 HEU infants were included of whom 155 (26%) were not 
exposed to ARVs, 114 (19%) were exposed early (first trimester) and 319 (54%) 
later. WAZ were lower among infants exposed early compared with infants 
exposed later: adjusted differences were −0.52 (95% confidence interval [CI]: 
−0.99 to −0.04, P = 0.02) at birth and −0.22 (95% CI: −0.47 to 0.04, P = 0.10) 
during follow-up. LAZ were lower during follow-up: −0.35 (95% CI: −0.63 to 
−0.08, P = 0.01). There were no differences in weight-for-length scores. Z-scores 
of infants exposed late during pregnancy were similar to unexposed infants.
Conclusions: In HEU children, early exposure to ARVs was associated 
with lower WAZ at birth and lower LAZ up to 2 years of life. Growth of 
HEU children needs to be monitored closely.
Key Words: antiretrovirals, HIV-exposed but uninfected children, birth 
weight, birth length, weight-for-age, length-for-age, Brazil
(Pediatr Infect Dis J 2016;35:71–77)
Antiretroviral drug (ARV) regimens for the prevention of mother-to-child transmission (PMTCT) of HIV have evolved 
in recent years.1 In 2010, the World Health Organization (WHO) 
published revised guidelines that recommended life-long ARVs 
for all persons, including pregnant women, with a CD4+ cell count 
≤350 cells/mm3 or the presence of WHO stage III or IV disease.2 
For pregnant women with CD4+ cell counts >350 cells/mm3 and 
without WHO stage III or IV disease, WHO recommended either 
option A or option B. Option A consists of maternal zidovu-
dine during pregnancy, maternal single dose nevirapine at deliv-
ery and the combination of maternal zidovudine and lamivudine 
from delivery to 1 week postpartum, as well as infant nevirapine 
throughout breastfeeding. Option B involves the maternal use of 
triple combination antiretroviral therapy (cART) during pregnancy 
and breastfeeding. In April 2012, WHO added option B+, which 
advocates life-long cART for all pregnant women, independent of 
CD4+ cell count or clinical stage. Of note, option A ceased to be 
recommended in 2013.3
Although ARVs in general and cART in particular virtu-
ally abolish mother-to-child transmission of HIV and the benefits 
clearly outweigh the potential risks, there are concerns about the 
effects of in utero exposure to ARVs on birth outcomes, postna-
tal growth and development of infants born to mothers with HIV 
infection.4–7 A study from Botswana showed that exposure to cART 
during pregnancy (initiated before conception or started during 
pregnancy) was associated with low birth weight and other adverse 
birth outcomes compared with zidovudine monotherapy started 
later during pregnancy.8 Growth trajectories after birth are also of 
concern. A study of infants born to mothers with HIV infection in 
Tanzania found that antiretroviral therapy (ART) during pregnancy 
was associated with an increased risk of wasting during follow-up, 
after adjusting for HIV infection, CD4 cell count and other poten-
tial confounding factors.9 A recent systematic literature review con-
cluded that it remains unknown whether in utero exposure to ARVs 
has alasting impact on infant growth.7
In Brazil, a large-scale public PMTCT program was intro-
duced in 1996,10 and the option B+ strategy was adopted in 2013. 
We previously analyzed infants born to women with HIV infection 
followed in a HIV reference center in Rio de Janeiro. We found that 
infants born to women who were receiving ART before pregnancy 
were more likely to be born preterm and have low birth weight than 
infants born to women treated after the first trimester.6 In this study, 
we aimed to evaluate whether exposure to ARV in the first trimester 
affects growth in the first 2 years of life in HIV-exposed but unin-
fected (HEU) infants born to the mothers of the Rio de Janeiro cohort.
METHODS
Setting and Definitions
We analyzed data collected prospectively at the Instituto de 
Puericultura e Pediatria Martagao Gesteira at Universidade Federal 
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do Rio de Janeiro, a tertiary care pediatric hospital in Rio de Janeiro, 
with a pediatric HIV clinic that cares for more than 1000 HEU 
infants and more than 400 HIV-infected children. HIV-infected 
mothers are counseled not to breastfeed; replacement feeding is 
provided free of charge in the first 12 months. HIV-exposed infants 
receive zidovudine until 6 weeks of life and afterward cotrimoxazole 
prophylaxis until the infant has had 2 undetectable viral load meas-
urements. For this analysis, 1 undetectable viral load measurement 
at least 6 weeks after birth was required to exclude HIV infection. 
The Roche Amplicor HIV-1 Monitor test was used to determine 
viral load, with a detection limit of 400 copies/mL.
Women were classified as having received no ARVs, zido-
vudine monotherapy, dual therapy or cART during pregnancy. If 
a woman changed regimens, the regimen with the larger number 
of drugs was used in the analysis. If she switched between nonnu-
cleoside reverse transcriptase inhibitor–based cART and protease 
inhibitor (PI)-based cART, the regimen received for longer was 
used in the analysis.
Inclusion Criteria and Follow-up Visits
All HEU singleton births after 1995 with at least 1 follow-
up visit were included in the analysis. Gestational age was based 
on newborn examination using the method proposed by Capurro 
et al.11 The gestational and perinatal history was extracted from 
the child’s immunization card and the mother’s antenatal card. 
Infants with congenital abnormalities were excluded. For each eli-
gible HEU child, a structured questionnaire was completed at care 
initiation and subsequent clinic visits. The data covered maternal 
age, HIV status, use and type of ART and the results of labora-
tory tests, including syphilis screening, CD4 cell count, viral load, 
hemoglobin and urine tests. All measurements were done at the 
first antenatal care (ANC) visit. Data on birth weight, birth length, 
gestational age at birth, mode of delivery, Apgar scores and use 
of ARVs during labor and delivery were obtained. Children were 
scheduled to be followed up in monthly intervals in the first year 
and every 3 months afterward. At each visit, clinical and laboratory 
data, prophylactic zidovudine use and other treatments and immu-
nizations were recorded.
Measurements of Weight and Length
At each visit, a trained assistant nurse measured weight with 
a mechanical weighing scale that was calibrated daily. Recumbent 
length was measured using a measuring board. Standard normal 
deviates (z-scores) for weight-for-age (WAZ), length-for-age 
(LAZ) and weight-for-length (WLZ) were calculated using the 
2003 Fenton preterm growth charts (until 50 weeks of gestational 
age) and the 2006 WHO child growth standards for infants born at 
term.12,13
Statistical Analysis
We analyzed LAZ, WAZ and WLZ scores at birth and up 
to the age of 2 years. The data were collected from January 1996 
to September 2010. We compared scores between children whose 
mothers had been exposed to ARVs in the first trimester (early ARV 
group), children whose mothers were exposed in the second or third 
trimester (late ARV group) and children whose mothers were not 
exposed to ARVs during pregnancy (no ARV group). We compared 
characteristics of children at birth and of mothers at their first ANC 
visit and at delivery. Continuous variables were described using 
medians and interquartile ranges; Kruskal-Wallis tests were used 
to test the null hypothesis of no difference across the 3 groups. Cat-
egorical variables are presented as numbers and percentages, with 
differences tested by Fisher exact tests.
We used linear regression to evaluate differences in z-scores 
at birth between comparison groups and multilevel mixed-effects 
linear regression models to examine the evolution of anthropomet-
ric measurements over time, with the random effect on the child 
and fixed effects on intercept and independent variables. Because 
growth is not linear over time, we introduced splines with knots at 
4.5 and 9.6 months to improve the fit of the model.14 We included 
mother’s age (younger than 25 years or older), maternal CD4 cell 
count at ANC initiation (square root transformed), maternal viral 
load at ANC initiation (undetectable or detectable), year of birth 
and family income (as continuous variables) in multivariable mod-
els. We also examined the evolution of anthropometric measure-
ments restricting the analysis to children exposed to cART during 
pregnancy, defined as use of at least 3 drugs, from at least 2 classes. 
Numbers were too small to allow further subgroup analyses.
Results from regression models are presented as differences 
in z-scores with 95% confidence intervals (CIs). P values <0.05 
were considered significant. STATA 13.0 (Stata Corp., College Sta-
tion, TX) was used for all analyses.
RESULTS
Characteristics of Mothers and Infants
Of 609 HEU children followed in this cohort, 8 pairs of 
twins, 4 children with missing date of birth and 1 infant with tri-
somy 21 were excluded, resulting in a study population of 588 HEU 
children. One hundred fifty-five (26.4%) children were not exposed 
to ARVs in utero, 114 (19.4%) were exposed in the first trimester 
(early ARV exposure) and 319 (54.2%) were exposed in the second 
or third trimester (later exposure). Forty (35.1%) of the 114 women 
on ARVs in the first trimester started therapy before conception.
Mothers exposed to ARV during pregnancy had higher CD4 
cell counts and lower viral loads at their first visit to ANC than 
mothers not exposed to ARV (Table 1). Mothers of infants exposed 
early in pregnancy were slightly older than mothers exposed later 
or not exposed to ARVs. The median family income was US$ 592 
in all 3 groups, corresponding to 2 minimum Brazilian wages of the 
year 2010.15 Most of the 114 children exposed early in pregnancy 
were born to mothers who received cART: 53 (46%) were exposed 
to PIs nelfinavir or lopinavir/ritonavir and 32 (28%) to nevirapine 
or efavirenz. The majority of children exposed later in pregnancy 
had been born to mothers who received zidovudine monotherapy or 
dual therapy (Table 1).
A total of 275 (46.7%) infants were female (Table 1). The 
median gestational age at birth was 38 weeks in all 3 groups; 
however, birth weight was lower in infants exposed to ARV in 
the first trimester (2.92 kg) compared with infants not exposed to 
ARV (2.97 kg) or infants exposed in the second or third trimes-
ter (3.04 kg; P = 0.02), with corresponding differences in WAZ 
scores (Table 1). Differences in birth length and LAZ scores failed 
to reach conventional levels of statistical significance (P = 0.07). 
Four children died during follow-up, 1 in the no ARV group and 3 
in the late ARV group. One child died of presumed meningococcal 
disease and 3 children died of pneumonia. One hundred eighty-one 
(30.8%) children were followed up for at least 2 years; the median 
follow-up was approximately 13 months in all groups.
Determinants of WAZ, LAZ and WLZ at Birth and 
Up to 2 Years
A total of 2107 weights and 2091 lengths were measured 
up to 2 years of age. Seven weight and 17 length measurements 
during follow-up resulted in z-scores below −4 or above +4 and 
were excluded. The median number (interquartile range) of meas-
urements per child was 7.0 (2–13) in the no ARV group, 6.1 
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(1–14) in the early ARV group and 6.2 (1–13) in the late ARV 
group (P = 0.10).
The number of children included in the multivariate analy-
ses ranged from 319 children (54.3%; LAZ at birth) to 359 children 
(61.1%; WAZ over time). The remaining children were excluded 
because of missing values. The characteristics of children included 
in the multivariate analyses were similar to the characteristics of 
all children. The results for WAZ at birth and its evolution over 
time are shown in Table 2. The difference in WAZ between infants 
exposed early in pregnancy and infants exposed later, adjusted for 
mother’s age, CD4 cell count, viral load, calendar year of birth and 
family income was −0.52 (95% CI: −0.99 to −0.04; P = 0.02). The 
corresponding estimate for the evolution of WAZ up to 2 years of 
age was −0.22 (95% CI: −0.47 to 0.04; P = 0.10). The evolution 
of LAZ over time, but not at birth, was less favorable in children 
exposed to ARVs in the first trimester (Table 3): the adjusted differ-
ence compared with infants exposed later in pregnancy was −0.35 
(95% CI: −0.63 to −0.08; P = 0.01). There was a difference at birth 
for WLZ (adjusted difference: −0.40; 96% CI: −0.80 to 0.003, 
P = 0.05) but no difference during follow-up (Table 4). The 
observed and the predicted evolution of WAZ, LAZ and WLZ from 
birth to 2 years of age from the mixed-effects regression models are 
shown in Figure 1.
The evolution of WAZ and LAZ was similar when we 
restricted the analysis to children exposed to cART: the WAZ and 
LAZ differences between infants exposed earlier and later in preg-
nancy were −0.21 (95% CI: −0.50 to 0.09; P = 0.17) and −0.31 
(95% CI: −0.62 to 0.00; P = 0.05), respectively. There were no 
statistically significant differences for WAZ (adjusted difference: 
0.15; 95% CI: −0.61 to 0.92), LAZ (−0.49; 95% CI: −1.14 to 0.15) 
or WLZ (0.53; 95% CI: −0.13 to 1.18) between the 85 infants 
exposed to tenofovir and tenofovir-unexposed infants.
DISCUSSION
In this cohort of HEU newborns in Rio de Janeiro, we 
found that birth weights were lower among infants exposed to 
ARVs during the first trimester compared with infants exposed 
to ARVs later during pregnancy or not exposed in utero. Differ-
ences in WAZ scores were statistically significant at birth, even 
after adjusting for mother’s age, CD4 cell count, family income 
and other potential confounders. The differences in WAZ scores 
became less important during the first 2 years of life. In con-
trast, there was no statistically significant difference in length 
at birth, but LAZ scores were lower throughout the second year 
of life in boys and girls exposed to ARVs early in pregnancy, 
TABLE 1. Characteristics of Pregnant Women and Their HIV-exposed but Uninfected Infants by Exposure to 
Antiretroviral Drugs During Pregnancy
Characteristic  
(Number of Children With Values)
No ARV in  
Pregnancy (N = 155)
ARV in the First  
Trimester (N = 114)
ARV in Second or Third 
 Trimester (N = 319) P Value*
Mothers
  CD4 cell count at first visit, cells/μL (N = 415) 288 (205 to 486) 371 (333 to 525) 444 (307 to 597) 0.0004
  Viral load at first visit, copies/mL (N = 376) 7332 (1070 to 30,325) 1608 (0 to 26,750) 6272 (1300 to 24,000) 0.03
  Age at delivery, yr (N = 569) 27.0 (23 to 32) 28.5 (25 to 34) 26.0 (22 to 30) 0.0007
  ARVs during pregnancy
   None 155 (100) 0.0001
   ZDV monotherapy 18 (16) 134 (42)
   Dual therapy 11 (10) 55 (17)
   NNRTI-based cART 32 (28) 37 (12)
   PI-based cART 53 (46) 93 (29)
  Family income, minimum wages† (N = 407) 2 (1 to 3) 2 (1 to 3) 2 (1 to 3) 0.11
Infants
  Gender (female) 68 (44) 55 (48) 152 (48) 0.69
  Year of birth
   1996–2000 17 (11) 10 (9) 29 (9) 0.94
   2001–2005 98 (63) 71 (62) 197 (62)
   2006–2010 40 (26) 33 (29) 93 (29)
  Gestational age at birth, wk (N = 422) 38 (38 to 39) 38 (37 to 39) 39 (38 to39) 0.12
  Prematurity‡ (N = 428) 4 (7.7) 13 (13.2) 36 (12.9) 0.55
  Small for gestational age (N = 432) 4 (7.1) 14 (14.3) 16 (5.8) 0.03
  Birth weight, kg (N = 575) 2.97 (2.61 to 3.29) 2.92 (2.6 to 3.3) 3.04 (2.78 to 3.39) 0.02
  Birth length, cm (N = 531) 48 (46 to 50) 48 (47 to 50) 49 (47 to 51) 0.07
  Birth WAZ (N = 575) −0.65 (−1.47 to 0.10) −0.78 (−1.59 to −0.02) −0.53 (−1.13 to 0.24) 0.04
  Birth LAZ (N = 531) −0.62 (−1.69 to 0.36) −0.81 (−0.52 to 0.46) −0.47 (−1.52 to 0.47) 0.07
  Birth WLZ (N = 531) −0.41 (−1.30 to −0.68) −0.37 (−1.19 to −0.31) −0.38 (−1.28 to −0.64) 0.65
  Length of follow-up, mo (N = 588) 12.6 (7.0 to 17.4) 12.7 (6.6 to 17.5) 13.3 (8.2 to 17.3) 0.36
  Number of visits (mo)
   0–6 690 (26) 500 (19) 1423 (54) 0.10
   7–12 333 (26) 247 (19) 734 (55)
   13–18 156 (26) 156 (19) 333 (55)
   19–24 72 (23) 58 (18) 189 (59)
  Number of children in follow-up (mo)
   0–6 155 (100) 114 (100) 319 (100) 0.54
   7–12 114 (74) 90 (79) 257 (81)
   13–18 88 (57) 71 (62) 202 (63)
   19–24 52 (34) 42 (37) 133 (42)
*P values from Kruskal-Wallis tests (continuous variables) and Fisher exact tests (categorical variables).
†1 Brazilian minimum wage = 296 US$ in 2010 (17).
‡Gestational age <37 weeks at birth.
NNRTI indicates nonnucleoside reverse transcriptase inhibitor; ZDV, zidovudine.
Data are presented as median (interquartile ranges) and percentages.
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Hofer et al The Pediatric Infectious Disease Journal • Volume 35, Number 1, January 2016
74  |  www.pidj.com  © 2015 Wolters Kluwer Health, Inc. All rights reserved.
corresponding to a difference in length of 1–2 cm at 2 years. Pre-
vious studies of birth weight and length have generally compared 
women on cART for their own health with women receiving 
short-term zidovudine courses later in pregnancy.8,16–18 Therefore, 
the time of exposure to ARVs correlated with the CD4 cell count 
in the mother and the number of drugs the unborn child was 
exposed to, which made it difficult to disentangle effects. The 
study by van der Merwe et al18 is an exception because it exam-
ined the effect of cART on the risk of low birth weight in immu-
nocompromised South African women who received cART either 
early (before 28 weeks of pregnancy) or later in pregnancy. The 
authors concluded that in utero exposure to cART was not asso-
ciated with low birth weight; however, the association was also 
confounded by maternal CD4 counts.18 In contrast, a study from 
Botswana showed a higher risk of small for gestational age births 
in mothers who started cART before conception, compared with 
mothers who started cART during pregnancy.8 Few studies from 
resource-limited settings have examined the association of in 
utero exposure to ARVs on growth after birth.9,19,20 A large cohort 
of over 2000 HEU infants followed up for 2 years in Tanzania 
showed that the risk of wasting was increased among HEU infants 
whose mothers were taking cART during pregnancy, even after 
adjusting for maternal CD4 cell counts.9 Unfortunately, the CD4 
cell counts in mothers and gestational week of starting cART were 
not reported. A follow-up study of 1076 children born to moth-
ers enrolled in a PMTCT trial in Thailand found that children 
exposed to zidovudine for more than 7.5 weeks had slightly lower 
birth weights (z-score difference: −0.08) than children exposed 
for a shorter period, but evolution of weight from 6 weeks to 18 
months of age was similar in the 2 groups.19 An analysis of the 
Mashi and MmaBana PMTCT studies from southern Botswana 
compared growth in 1059 HEU children born to women who 
either received a short course of zidovudine at 34 weeks of gesta-
tion or initiated cART between 18 and 34 weeks of gestation.20 
TABLE 2. Regression Analyses of Weight-for-Age z-Scores at Birth and Their Evolution 
Over Time by Exposure to Antiretroviral Drugs
Univariable Linear  
Regression of WAZ at Birth  
(N = 575)
Multivariable Linear  
Regression of WAZ at Birth*  
(N = 359)
Difference in WAZ  
(95% CI) P Value
Difference in WAZ  
(95% CI) P Value
ARVs in the first trimestwer −0.30 (−0.55 to −0.06) 0.02 −0.52 (−0.99 to −0.04) 0.02
No ARVs during pregnancy −0.20 (−0.43 to 0.02) 0.07 0.30 (−0.08 to 0.69) 0.12
ARVs in the second or third trimester 0 (reference) — 0 (reference) —
Univariable Mixed-effects  
Regression of WAZ Over Time  
(N = 582)
Multivariable Mixed-effects  
Regression of WAZ Over Time*  
(N = 358)
Difference in WAZ  
(95% CI) P Value
Difference in WAZ  
(95% CI) P Value
ARVs in the first trimester −0.17 (−0.40 to 0.06) 0.15 −0.22 (−0.47 to 0.04) 0.10
No ARVs during pregnancy −0.19 (−0.40 to 0.01) 0.07 −0.01 (−0.34 to 0.36) 0.96
ARVs in the second or third trimester 0 (reference) — 0 (reference) —
*Adjusted for mother’s age (younger than 25 years or older), CD4 cell count (square root transformed), viral load (undetectable or 
detectable), year of birth and family income. N = 358 children.
TABLE 3. Regression Analyses of Length-for-Age z-Scores at Birth and Their Evolution 
Over Time by Exposure to Antiretroviral Drugs
Univariable Linear  
Regression of LAZ at Birth  
(N = 531)
Multivariable Linear  
Regression of LAZ at Birth*  
(N = 319)
Difference in LAZ  
(95% CI) P Value
Difference in LAZ  
(95% CI) P Value
ARVs in the first trimester −0.56 (−0.25 to 0.06) 0.11 −0.05 (−0.41 to 0.30) 0.76
No ARVs during pregnancy −0.21 (−0.50 to 0.08) 0.15 0.26 (−0.23 to 0.75) 0.30
ARVs in the second or third trimester 0 (reference) — 0 (reference) —
Univariable Mixed-effects  
Regression of LAZ Over Time  
(N = 577)
Multivariable Mixed-effects  
Regression of LAZ Over Time  
(N = 356)
Difference in LAZ  
(95% CI) P Value
Difference in LAZ  
(95% CI) P Value
ARVs in the first trimester −0.27 (−0.52 to −0.01) 0.04 −0.35 (−0.63 to −0.08) 0.01
No ARVs during pregnancy −0.23 (−0.45 to −0.001) 0.05 0.12 (−0.25 to 0.49) 0.53
ARVs in the second or third trimester 0 (reference) — 0 (reference) —
*Adjusted for mother’s age (younger than 25 years or older), CD4 cell count (square root transformed), viral load (undetectable or 
detectable), year of birth and family income. N = 356 children.
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Similar to our study, the authors found that differences in WAZ 
disappeared during follow-up, whereas LAZ remained lower 
in cART-exposed infants. Finally, a follow-up of 182 children 
born to mothers enrolled in the Development of AntiRetroviral 
Therapy in Africa (DART) trial found little evidence that in utero 
exposure to tenofovir affected growth after 2 years.21 Although 
other studies demonstrated lower LAZ and head circumference 
adjusted for age in 1-year-old infants in utero exposed to ten-
ofovir,22 and lower WAZ at 6 months, for infants late in utero 
(second and third trimester) exposed to tenofovir.23
Strengths and Limitations
The relatively high maternal CD4 counts, which make con-
founding by immune status unlikely, and the follow-up up to 2 
years of age are important strengths of our study. Another strength 
is that exposure included zidovudine monotherapy, dual therapy 
and cART and that we could distinguish between first trimester 
and later trimester exposure to ARVs. Previous studies did not gen-
erally examine the time of in utero exposure to ARVs but simply 
compared exposed with unexposed HEU children,4,16–18 which may 
explain some of the discrepant and inconsistent results observed 
in these studies. Furthermore, follow-up was often relatively short, 
6–18 months.19,20 Finally, growth trajectories over the first few years 
of life are meaningful predictors of height in later childhood and of 
final height.24
Our study has several limitations. We analyzed weight and 
length measurements taken during routine care rather than meas-
urements taken in a standardized manner for research purposes. 
Although this is unlikely to have biased our results, it will have 
introduced additional observer and instrument variability and 
reduced the power of our study. Also, intervals between visits and 
duration of follow-up varied, as expected in routine clinical prac-
tice, but our statistical models accounted for differences in inter-
vals and loss to follow-up. The differences in growth observed in 
our study are not proof of a causal relationship between in utero 
exposure to ARVs and reduced growth. This was an observational 
study and the characteristics of the groups differed. For example, 
the children exposed in utero early during pregnancy tended to be 
exposed to cART, whereas most of the children exposed later were 
exposed to zidovudine monotherapy or dual therapy.
However, results were similar when excluding PI-based 
cART. Because of the limited sample size, no further stratifica-
tion was possible. Other variables that could confound associa-
tions were well balanced between groups, including gestational 
age and median family income. However, we cannot exclude that 
residual confounding or confounding by variables not measured 
in this study could have distorted results. For example, we could 
not adjust for maternal height and weight or tobacco and illicit 
drug use.
Possible Pathways and Mechanisms
Several mechanisms that could explain reduced intrauterine 
and postnatal growth in HEU children exposed to ARVs in utero 
exist, but further research is needed to clarify their respective role. 
For example, studies in rhesus macaques exposed in utero to high 
doses of tenofovir showed reduced levels of insulin-like growth 
factor-1 and reduced intrauterine growth.7 Mitochondrial toxicity 
is another possible pathway.7 In a Canadian cohort of HEU infants 
exposed to cART in utero plasma lactate levels were increased dur-
ing the first 6 months of life,25 possibly as a consequence of mito-
chondrial toxicity that may persist for several years.26 Many path-
ways of intermediary metabolism, including fatty acid oxidation, 
organic acid metabolism and amino acid metabolism, depend on 
normal oxidative phosphorylation and therefore could be affected 
by mitochondrial toxicity.27 Interestingly, a comparison of acylcar-
nitine levels in HEU infants exposed and not exposed to ARVs in 
utero, based on the New York state newborn screening data, showed 
that abnormal acylcarnitine levels were more frequent in ARV-
exposed infants.28
Implications and Further Research
Our study indicates that HEU children who experienced 
first trimester in utero exposure to ARVs are shorter than their 
unexposed peers and may face similar problems with social 
stigma as HIV-infected children and children of short stature in 
general.29–32 We agree with Owor et al that HEU children should 
be identified early, their growth should be carefully monitored 
and early nutritional interventions should be provided to infants 
and children with poor growth. Cotrimoxazole prophylaxis in 
the first year of life and the timely treatment of diarrhea and 
TABLE 4. Regression Analyses of Weight-for-Length z-Scores at Birth and Their Evolution 
Over Time by Exposure to Antiretroviral Drugs
Univariable Linear  
Regression of WLZ at Birth  
(N = 501)
Multivariable Linear  
Regression of WLZ at Birth*  
(N = 300)
Difference in WLZ  
(95% CI) P Value
Difference in WLZ  
(95% CI) P Value
ARVs in the first trimester −0.18 (−0.53 to 0.16) 0.29 −0.40 (−0.80 to 0.003) 0.05
No ARVs during pregnancy 0.04 (−0.36 to 0.29) 0.83 0.24 (−0.34 to 0.82) 0.42
ARVs in the second or third trimester 0 (reference) — 0 (reference) —
Univariable Mixed-effects  
Regression of WLZ Over Time  
(N = 577)
Multivariable Mixed-effects  
Regression of WLZ Over Time  
(N = 340)
Difference in WLZ  
(95% CI) P Value
Difference in WLZ  
(95% CI) P Value
ARVs in the first trimester 0.01 (−0.19 to 0.22) 0.91 0.03 (−0.20 to 0.26) 0.80
No ARVs during pregnancy −0.01 (−0.20 to 0.17) 0.88 −0.12 (−0.42 to 0.18) 0.43
ARVs in the second or third trimester 0 (reference) — 0 (reference) —
*Adjusted for mother’s age (younger than 25 years or older), CD4 cell count (square root transformed), viral load (undetectable or detectable), 
year of birth and family income. N = 356 children.
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respiratory infections are also important in this context.33 
Finally, in light of the roll-out of the option B+ strategy for 
PMTCT, further studies of childhood growth and development, 
with detailed data on the timing and type of in utero exposure 
to ARVs, are needed. Collaborative studies combining data from 
different settings would be a logical next step, for example, 
within the framework of the NICHD International Site Devel-
opment Initiative (NISDI) in Latin America34 or the Interna-
tional epidemiological Databases to Evaluate AIDS (IeDEA) in 
sub-Saharan Africa.35
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children; splines were introduced with knots at 4.5 and  
9.6 months.
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